Björn G. Appelberg, MD, PhD

  • 2Articles
  • 17.4KReads
  • 2001–2021Active
  • 8Collaborators
  • 3Citations

About

Björn G. Appelberg, MD, PhD, is affiliated with the Department of Psychiatry at Helsinki University Hospital in Helsinki, Finland. His publications from 2001 to 2021 focus on neuropsychiatric conditions including Alzheimer disease, cognition, depression (MDD), and neurology. His work includes studies on brain atrophy related to cognitive decline in elderly patients with first-episode psychosis and the augmentation of selective serotonin reuptake inhibitors with buspirone in severe depression. He has frequently collaborated with Erkka K. Syvälähti, Hannu H. Naukkarinen, Juha Martola, Kati Juva, and Olli-Pekka Mehtonen.

Publications

PCC
Original Research

Brain Atrophy, Cognitive Decline, and First-Episode Psychosis

November 11, 2021

The etiology of first-episode psychosis (FEP) in the elderly is unknown, but an underlying neurodegenerative disorder may be an important factor. To investigate further, this study assessed brain atrophy...
, , , et al
JCP
Original Research

Patients With Severe Depression May Benefit From Buspirone Augmentation of Selective Serotonin Reuptake Inhibitors: Results From a Placebo-Controlled, Randomized, Double-Blind, Placebo Wash-In Study

June 1, 2001

, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Psychedelics in Psychiatry

Explore the Collection
Neural network illustration symbolizing psychedelic research advancements

Subscribe to read
more articles

Subscribe